ATG7
ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
Overview
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.89, genetic association 0.34, somatic mutation 0.36). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Renal Clear Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
- 1 · What it is
ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
- 2 · What goes wrong in cancer
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy.
- 3 · How drugs use it
No product in this corpus aims at ATG7 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:16935 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95352 (protein name, function text, keywords and locations (REST API)); CIViC gene ATG7 (1 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000197548 (association with cancer (MONDO_0004992) 0.64; (GraphQL API, CC0)); IntOGen ATG7 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Facilitates LC3-I lipidation with phosphatidylethanolamine to form LC3-II which is found on autophagosomal membranes. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Location: Cytoplasm; Preautophagosomal structure (UniProt). Locus 3p25.3 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Clear cell renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ATG7" OR ABSTRACT:"ATG7" OR TITLE:"autophagy related 7" OR ABSTRACT:"autophagy related 7" OR TITLE:"Ubiquitin-like modifier-activating enzyme ATG7" OR ABSTRACT:"Ubiquitin-like modifier-activating enzyme ATG7" OR TITLE:"GSA7" OR ABSTRACT:"GSA7" OR TITLE:"DKFZp434N0735" OR ABSTRACT:"DKFZp434N0735" OR TITLE:"APG7L" OR ABSTRACT:"APG7L") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATG7, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKDM5C
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
- TargetARHGEF10L
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetRAP1GDS1
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetMSN
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetPTPRK
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetARHGEF12
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetCHD4
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetCLTC
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.